Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Linvencorvir in Healthy Chinese Subjects
NCT03570658Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of linvencorvir in hepatitis B (HBV) (3 arms), sponsored by Roche. Primary endpoint: Percentage of Participants With Adverse Events. Started Aug 2018; status: completed.
02
Drugs
linvencorvir
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03570658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570658.